NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Targets Hepatic Encephalopathy, a Complication of Liver Cirrhosis, with OCR-002
Ocera Therapeutics (NASDAQ: OCRX) is focused on the development of OCR-002 (ornithine phenylacetate) to treat hyperammonemia and subsequent hepatic encephalopathy (HE). An estimated eight million people in the U.S. suffer from chronic liver disease and approximately one million suffer from liver cirrhosis. HE is a debilitating and progressive complication of liver cirrhosis or liver failure marked by mental changes including confusion, impaired motor skills, and disorientation. Severe HE can cause stupor, coma and even death. Currently, there are no drug treatments that can be given intravenously to hospitalized patients with acute HE. To learn more visit www.ocerainc.com About Ocera Ocera…







